Oral Cancer Expert Finds Unexpected Treatment Breakthrough From Raspberries and Old Breast Cancer Therapy
Article ID: 585028
Released: 27-Jan-2012 9:00 AM EST
Source Newsroom: Ohio State University Center for Clinical and Translational Science
Newswise — Dr. Susan Mallery, a professor in the College of Dentistry at The Ohio State University and Oral Pathology Consultant at the Ohio State University and James Cancer hospitals, has dedicated her nearly 30-year career to studying new strategies to preventing oral cancer. Oral cancer is currently responsible for more than 7,000 deaths each year, and has a particularly high mortality rate. Treatment relies on excising cells before they turn cancerous, but as many as one-third of all patients will experience a recurrence within a year.
“While not all oral lesions progress to cancer, we cannot accurately predict which will be the ‘bad actors.’ This often results in multiple surgeries and high anxiety in both our patients and clinicians,” says Mallery.
Since 2003, Mallery has been investigating a variety of agents ranging from anti-angiogenesis drugs to natural products, to identify new therapeutics that can suppress the conversion of pre-cancerous to cancerous cells. Her first breakthrough was the creation of an oral gel based on anthocyanins, powerful antioxidants found in black raspberries. Study results showed that the gel, when applied to the mouth, would suppress genes associated with functions that allow cancerous cells to grow, thus diminishing the risk for recurring lesions.
Mallery next turned her attention to identifying alternatives to the surgical removal of pre-cancerous lesions. Mallery thought she might have good possibilities with fenretinide, a decades-old breast cancer treatment that had been largely abandoned by oral pathologists despite strong clinical evidence that showed fenretinide can induce cell death, encourage the body’s natural cellular defense system and strangle blood supply to tumors.
“The discrepancy between the established efficacy of fenretinide in other cancer types and in oral cancer was puzzling. Then it occurred to me that maybe the structure of the oral mucosa wasn’t allowing a therapeutic amount to reach the lesions, even at high doses,” says Mallery. “We knew we needed to come up with a way to deliver the therapy directly to the lesion”
In 2009, The Ohio State University College of Dentistry, in collaboration with the Center for Clinical and Translational Science (CCTS) awarded Mallery and her team funding for a project aimed at developing a way to treat precancerous lesions directly in the mouth and preventing recurring lesions.
Mallery partnered with two pharmaceutical chemists from the University of Michigan (Drs. Stephen Schwendeman and Kashappa Goud Desai) along with two Ohio State investigators Drs. Gary Stoner and Peter Larsen to develop a first of its kind patch that could stick to the inside of the mouth, and deliver a continuous therapeutic dose of fenretinide directly on the lesion.
The research team plans to move the patch into pre-clinical and clinical trials, and is already looking at a combination of fenretinide and anthocyanins, as well as testing a combination therapy using the patch and black raspberry-based gel mouthwash to prevent recurrence of lesions.
“If we can effectively treat the lesions with the patch, and then prevent more from coming back, we will completely change – and improve upon – the way oral cancer is currently treated,” said Mallery.
Mallery says the best course of action is to prevent oral cancer in the first place, and provides the following tips:• Use of tobacco products – particularly burned tobacco – is the greatest risk factor for development of oral cancer.• Watch what you drink and eat. Alcohol consumption – in excess and especially during smoking – can have an additive effect and increase your chances to develop oral cancer. Conversely, a diet high in fruits and vegetables can lower your risk.• Infection with human papilloma viruses (HPV) causes a subset of oral cancers. Inoculation of both young women and men with the HPV vaccine would markedly decrease HPV-associated oral cancers.• Remember the mouth heals quickly. If you have a sore in your mouth that doesn’t heal in 14 days, seek prompt treatment from your dentist.• See your dentist at least once a year (better if twice a year) for a complete oral health screening. This is extremely important as oral cancer initially develops a precancerous oral lesions (patient treatment and survival is much better at this stage).
Currently, Dr. Mallery is Professor and Director of Research for the Division of Oral Surgery, Oral Pathology and Anesthesiology at the Ohio State University College of Dentistry. Dr. Mallery received her DDS from the Ohio State University in 1981, then practiced General Dentistry for nearly two years and completed a Research Fellowship at Georgetown University. She then returned to Ohio State University to complete her oral pathology specialty training and PhD, which were funded by an NIH Individual Dentist Scientist Award and joined Ohio State’s faculty in 1990. Since that time, she has participated in teaching at both the undergraduate dental student and graduate levels in addition to service with Oral Pathology Consultants. Much of Dr. Mallery’s time is directed towards cancer research. She has served as the Principle Investigator for several NIH funded R01 grants and she is currently the PI for a multicenter oral cancer clinical trial.
Dr. Mallery has lectured internationally and is widely published in peer reviewed journals. She is available for interviews to discuss the future of oral cancer treatment, oral cancer risk factors, and what consumers with high risk factors should look for.
About The Ohio State University Center for Clinical and Translational ScienceDedicated to turning the scientific discoveries of today into the life-changing health innovations of tomorrow, The Ohio State University Center for Clinical and Translational Science (OSU CCTS) is a collaboration of experts including scientists and clinicians from seven OSU Health Science Colleges, OSU Medical Center and Nationwide Children’s Hospital. Funded by a multi-year Clinical and Translational Science Award (CTSA) from the National Institutes of Health, OSU CCTS provides financial, organizational and educational support to biomedical researchers as well as opportunities for community members to participate in credible and valuable research. For more information, visit http://ccts.osu.edu or contact: Kim Toussant (email@example.com 614-366-7215).
About the Clinical and Translational Science AwardsLaunched in 2006 by the National Institutes of Health’s National Center for Research Resources (NCRR), Clinical and Translational Science Awards (CTSA) program created academic homes for clinical and translational science at research institutions across the country. The CTSA’s primary goals are to speed the time it takes for basic science to turn into useable therapeutic s that directly improve human health, and to train the next generation of clinicians and translational researchers.